Skip to main content Skip to footer
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.
  • Home
  • About Us
    • Our Story
    • Our Mission, Vision, Values
    • Our Team
    • Our Partners
    • Investors & Media
  • Patients
    • About Lupus Nephritis
    • Resources
    • Patient Support Program
    • Aurinia in Action
  • Our Science
    • Our Product
    • Our Pipeline
    • Our Research and Data
  • Investors & Media
    • News & Events
    • Corporate Presentation
    • Financial Info
    • Stock Data
    • SEC Filings
    • ESG
    • Board of Directors
    • Governance
    • Investor Tools
  • Aurinia Gives
    • Aurinia Gives
    • CME Grants
    • Charitable Giving FAQs
    • Sponsorships
    • Charitable Donations
    • Patient-Centered Care Grants
  • Careers
    • Our Culture
    • Our Benefits
    • Notice to Recruiters
    • Careers Contact
    • Open Positions
  • Contact Us
    • Report an Adverse Event

Press Releases

Investors & Media

Investors & Media

  • News & Events
    • Press Releases
    • IR Calendar
    • 2025 AGM
  • Corporate Presentation
    • Corporate Presentation
  • Financial Info
    • Financial Results
  • Stock Data
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
  • ESG
  • Board of Directors
  • Governance
  • Investor Tools
    • Overview
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News & Events

  • Press Releases
  • IR Calendar
  • 2025 AGM
February 11, 2016 • 1:47 pm EST

Aurinia to Host Conference Call & Webcast to Review Results from the AURION Study

February 8, 2016 • 8:30 am EST

Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis

February 4, 2016 • 4:30 pm EST

Aurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences

February 2, 2016 • 4:43 pm EST

Aurinia Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference

January 29, 2016 • 6:53 pm EST

Aurinia Pharmaceuticals to Present at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day

January 19, 2016 • 5:17 pm EST

Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis

November 24, 2015 • 8:30 am EST

Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned

November 13, 2015 • 4:15 pm EST

Aurinia Reports Third Quarter 2015 Financial Results

October 19, 2015 • 8:00 am EDT

Aurinia Pharmaceuticals to Present at the 14th Annual BIO Investor Forum

September 17, 2015 • 5:30 pm EDT

Aurinia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

<h2>We are passionate about changing the trajectory of autoimmune diseases.<br>Join us.</h2>

Business Development

bd@auriniapharma.com

Investor Relations

ir@auriniapharma.com

Clinical Trials

clinicaltrials@auriniapharma.com

Medical Information

medinfo@auriniapharma.com

Corporate Communications and Media Inquiries

AChristopher@auriniapharma.com

Patient Safety

Report an Adverse Event
Privacy Statement Terms of Use Disclaimer Aurinia Community Guidelines Aurinia Compliance Program Manage Cookie Preferences
©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23
Back to top

Navigating away from Aurinia

You are about to leave the Aurinia Pharmaceuticals website. We are not responsible for the content or accuracy of information on any third-party websites nor do we monitor or endorse such websites. If you would like to leave the Aurinia website and visit the third-party website, please select CONTINUE.